Antibody discovery just got a major upgrade. This groundbreaking 2023 study shows how combining mammalian display libraries with high-throughput microfluidic screening can accelerate the hunt for functional, drug-ready antibodies. By leveraging full immune repertoires in mammalian cells, the authors unlock antibody diversity with a unique “display-to-secretion” switchable system — giving you the best of both worlds.

At the heart of this approach? Sphere Bio’s Cyto-Mine® platform. Our picodroplet microfluidics technology makes it possible to rapidly screen millions of mammalian cells at single-cell resolution, all while maintaining cell viability and functional integrity. This study highlights how Cyto-Mine® powers a “Function First” screening strategy, prioritizing biologically relevant hits from the get-go — saving you time, reducing false positives, and supercharging your antibody discovery workflow.